Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Volume: 146, Issue: 1, Pages: 85 - 95
Published: Jan 1, 2014
Abstract
Background & Aims null Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) −α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF−α antagonist-naive patients with moderate-to-severe UC despite conventional treatment. null Methods null We integrated double-blind phase 2 dose-finding and phase 3 dose-confirmation trials in a study of...
Paper Details
Title
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Published Date
Jan 1, 2014
Volume
146
Issue
1
Pages
85 - 95
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.